Independent peptide intelligence
Est. 2026 · No commercial interestPeptide science,
without the hype.
A reference for peptides, peptide medicines, and the research around them. Every entry answers three questions, in order.
- I
What the compound is. Class, target, and route — stated plainly.
- II
What the evidence shows. Study type, population, and duration.
- III
Where it stands legally. Approval, investigational, or unreviewed.
News & updates
Today’s Peptide Brief
One regulatory item, one clinical research item, one science or industry item — summarised with status tags and links to primary sources.
Daily dossier
2026
Daily Peptide Brief
Three research streams · one development each · primary sources cited
- RegulatoryStream I
Agency reiterates warning on compounded and counterfeit incretin products
A renewed safety communication addresses unapproved GLP-1 preparations sold online, citing dosing errors and unverified content. Compounded preparations remain outside premarket review.
Not an approved productSource · Regulatory communication — primary source - Clinical researchStream II
Phase 3 triple-agonist programme reports interim safety data
Interim tolerability findings are consistent with earlier phase 2 gastrointestinal signals. Efficacy endpoints remain blinded; no approval exists for this compound in any jurisdiction.
Investigational — phase 3Source · Registry entry and sponsor disclosure - Science & industryStream III
Oral peptide delivery platform reports improved bioavailability in early study
A first-in-human pharmacokinetic study describes higher absorption using an absorption-enhancer formulation. Pharmacokinetic improvement does not establish clinical benefit.
Phase 1 — pharmacokineticsSource · Peer-reviewed publication
Daily intelligenceReference plates
Human Peptide Research Atlas
An orientation map for readers of clinical research, arranged by area of human biology. Each plate states how the literature is framed there and where the evidence is limited. Nothing here describes a treatment.
Plate 01Skin & Hair
Dermal and follicular biology holds the largest body of cosmetic-ingredient literature. Most published work reports laboratory or short-term appearance measures rather than clinical endpoints.
Cosmetic ingredient · No efficacy review required
Explore the research
Plate 02Metabolic Health
Incretin and metabolic signalling is the most heavily researched peptide domain, with several approved medicines studied in large randomised trials in defined populations.
Approved medicines exist · Evidence grade A–B
Explore the research
Plate 03Muscle & Recovery Research
Compounds discussed in this area have been studied mainly in cell and animal models. Controlled human data on recovery-related outcomes is sparse.
Research use only · Evidence is limited
Explore the research
Plate 04Joint & Connective Tissue Research
Tendon, cartilage and bone literature is dominated by orthopaedic and imaging research. Peptide-related work here remains largely mechanistic.
Mostly preclinical · Interpret cautiously
Explore the research
Plate 05Brain & Neurobiology
Neuropeptide research is constrained by the blood-brain barrier. Some targeted classes have registered clinical programmes; most marketed compounds do not.
Mixed: approved classes and unreviewed compounds
Explore the research
Plate 06Hormones & Endocrine Health
Growth hormone axis and related peptides have narrow approvals in specific diagnoses, alongside broad promotion that the evidence does not support.
Narrow approvals · Broad off-label promotion
Explore the research
Plate 07Sleep & Circadian Biology
Circadian and sleep-architecture research is measured with polysomnography and actigraphy. Peptide claims in this area rest mostly on small, short studies.
Small studies · Evidence is limited
Explore the research
Plate 08Healthy Aging Research
Longevity-framed peptide research is early. Biomarker changes reported in laboratory work have not been shown to translate into human outcomes.
Preclinical / early · Biomarkers are not outcomes
Explore the research
Educational reference only · Safety varies by compound and source · Discuss with a qualified clinician
Curated collections
Organised by therapeutic area, not by marketing category
Each collection explains the biology, the state of the evidence, and the open questions — with the regulatory picture stated up front.
Volume I
Metabolic peptides
Incretin-based medicines with large randomised trial programmes.
Volume II
Endocrine peptides
Growth hormone axis agents; narrow approvals, broad promotion.
Volume III
Bone health peptides
Anabolic bone therapies with fracture-outcome evidence.
Volume IV
Cardiovascular peptides
Natriuretic biology, diagnostics, and instructive failures.
Volume V
Oncology-related peptides
Targeted radionuclide therapy and hormone-axis suppression.
Volume VI
Neurology-related peptides
CGRP-targeted therapies and the blood-brain barrier problem.
Featured profile
A standardised peptide record
Semaglutide
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, chronic weight management. One of the most extensively studied peptide medicines in modern endocrinology.
- Classification
- Peptide analogue of human GLP-1 (incretin mimetic)
- Target / mechanism
- Glucagon-like peptide-1 (GLP-1) receptor
- Development status
- Marketed; multiple ongoing trials in new indications
- Route / formulation
- Subcutaneous injection; an oral tablet formulation also exists
- Last reviewed
- 2026-08-02
Research tracker
Pipeline at a glance
A serious research-monitoring view: stage, mechanism, and what each stage does and does not establish.
Development stages
Where peptide science currently sits
Stage indicates how far evaluation has progressed — not likelihood of success. Most candidates entering clinical development never reach approval.
- Preclinical
Next-generation amylin and dual-mechanism candidates
Cell and animal work; no human safety or efficacy data. - Phase 1
Oral peptide delivery platforms
First-in-human safety and pharmacokinetics. - Phase 2
Muscle-preserving co-therapies in weight management
Dose finding with body-composition endpoints. - Phase 3
Triple agonist programmes in obesity and diabetes
Confirmatory efficacy and safety at scale. - Approved
Incretin-based metabolic medicines
Marketed with defined indications and post-marketing surveillance.
Start here
Learn peptides from the ground up
Plain-English foundations with a scientific tone — written so a beginner can follow and an advanced reader still finds it precise.
Foundations
What Are Peptides?
A peptide is a short chain of amino acids. That single sentence hides a category that spans approved medicines, cosmetic ingredients, and unregulated online products.
Mechanism
How Peptides Work
Peptides mostly act as signals: they bind receptors and change cellular behaviour. Understanding receptor pharmacology explains most of what peptide medicines can and cannot do.
Systems
Peptide Biology
How the body makes, uses, and disposes of peptides — and why endogenous signalling systems constrain what external peptides can achieve.
Fig. 01 / Cellular context
Signalling pathways, illustrated
An editorial study of nerve, vascular and muscular pathways. Conceptual artwork used for orientation only — it does not depict any compound or outcome.
Safety & regulation
“Research use only” is a sales category, not a safety assessment.
The label signals only that a seller is not marketing the material as a medicine. It says nothing about identity, purity, sterility, or human safety.
These six categories are not interchangeable. Every profile on this site states which one applies before describing any effect.
Read the safety section
- FDA-approved01
Premarket review
Reviewed for a defined indication and population; labelled use is evidence-backed.
- Investigational02
Under study
Being evaluated in trials. Benefit-risk is not established and no approval exists.
- Compounded03
Not reviewed
Prepared outside premarket review for safety, efficacy, or manufacturing consistency.
- Research use only04
Not for humans
Sold as laboratory material. Never evaluated for human administration.
- Cosmetic05
Topical rules
Regulated for topical safety and claims; no efficacy review is required.
- Preclinical06
Cells & animals
Evidence exists only in vitro or in animal models. Human effects are unknown.
Methodology & trust
How this platform decides what to publish
Editorial standards are part of the product, not a footnote.
Status before claims
Every profile states regulatory status and evidence level before describing effects. Approval, investigational status, compounding, and 'research use only' are never treated as equivalent.
Primary sources
We cite regulators, trial registries, and peer-reviewed literature. Retailer pages, forums, and secondary blogs are not sources.
Calibrated language
We describe what was measured, in whom, and for how long. We avoid 'proven', 'heals', and 'optimises' unless a specific finding tightly supports it.
Dated and reviewed
Each page carries a last-reviewed date and a named reviewer role, so you can tell how current the assessment is.
No commercial interest
No product sales, no affiliate links, no sponsored placements, no dosing instructions. Documentation is not endorsement.
Uncertainty is content
Where evidence is thin or contradictory, we say so plainly instead of rounding it up to a recommendation.
Recent developments
Latest from the desk
Body-composition endpoints move to the centre of weight-management trials
Several programmes now prespecify lean mass measurement, reflecting a methodological shift rather than a proven clinical advantage.
Status · Phase 2 evidence
A peptide cardiovascular programme reports a null primary endpoint
Favourable biomarker changes did not translate into event reduction — a recurring pattern worth remembering when reading mechanism-led claims.
Status · Phase 3 — null result
Import measures target vials marketed as research peptides
Enforcement activity focuses on products whose labelling positions them outside medicine regulation while being marketed for human effects.
Status · Regulatory action
Additional peptide bulk substances placed under safety review for compounding
Evaluations cite incomplete characterisation and immunogenicity uncertainty. Review status is not an approval and not a prohibition on all use.
Status · Compounding
Directory sample
Profiles with status attached
Tirzepatide
Metabolic · Metabolic / endocrine
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with an expanding trial programme across cardiometabolic and sleep-related indications.
Retatrutide
Metabolic · Metabolic
An investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 data have been reported; it is not an approved medicine anywhere.
BPC-157
Musculoskeletal · Musculoskeletal / gastrointestinal (proposed)
A synthetic pentadecapeptide widely marketed online and frequently discussed in injury-recovery contexts. Human evidence is very limited, and it is not an approved medicine.
Daily Peptide Brief
Three developments a day, with status attached.
One regulatory item, one clinical research item, one science or industry item — each tagged with evidence level and regulatory status, each linked to a primary source. No product promotion, ever.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.